Abstract
The COVID-19 pandemic has initiated an unprecedented worldwide effort to characterize its evolution through the mapping of mutations of the coronavirus SARS-CoV-2. The early identification of mutations that could confer adaptive advantages to the virus, such as higher infectivity or immune evasion, is of paramount importance. However, the large number of currently available genomes precludes the efficient use of phylogeny-based methods. Here we establish a fast and scalable early warning system based on Topological Data Analysis for the identification and surveillance of emerging adaptive mutations in large genomic datasets. Analyzing millions of SARS-CoV-2 genomes from GISAID, we demonstrate that topologically salient mutations are linked with an increase in infectivity or immune escape. We report on emerging potentially adaptive mutations as of January 2022, and pinpoint mutations in Variants of Concern that are likely due to convergent evolution. Our approach can improve the surveillance of mutations of concern, guide experimental studies, and aid vaccine development.
Competing Interest Statement
Raul Rabadan is a founder of Genotwin, he is member of the Scientific Advisory Board of AimedBio and consults for Arquimea Research.
Funding Statement
The authors acknowledge the use of de.NBI Cloud and the support by the High Performance and Cloud Computing Group at the Zentrum für Datenverarbeitung of the University of Tübingen and the Federal Ministry of Education and Research (BMBF) through grant no 031 A535A. This research was supported by the DFG Collaborative Research Center SFB/TRR 109 ''Discretization in Geometry and Dynamics''. M.B. was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy EXC 2181/1 - 390900948 (the Heidelberg STRUCTURES Excellence Cluster). L.H. thanks the Evangelisches Studienwerk Villigst for their support. A.O. acknowledges funding by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) -- 281869850 (RTG 2229).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No specific IRB protocol as data can be found in public repositories (GISAID).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
SARS-CoV-2 genome data used in this work are available from the GISAID EpiCov Database at www.gisaid.org.
